Haemostatix’s innovative technology platform is based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or carrier protein to create both systemic and topical haemostats.

In the systemic formulation, the peptide is coupled to microparticles and, when administered, the peptide binds the patient’s own fibrinogen and this targets the microparticle to the formation of a clot at a wound site. The clot is completed by conversion of fibrinogen into fibre-like fibrin by the enzyme thrombin. The targeted peptide-microparticle physically augments clot formation, acting as a platelet substitute. The systemic formulation is the basis of the company’s lead product HaemoPlax, being developed for the prevention of bleeding in leukaemic, thrombocytopenic patients. More...

In the topical format, the peptide is coupled to a soluble carrier protein and forms a novel gel matrix with fibrinogen, acting as a potential topical haemostat or wound sealant. More...

In addition to coupling the fibrinogen binding peptide to different supports or carrier proteins, Haemostatix has also modified the peptide sequence to create a ‘pro-drug’ version of HaemoPlax, HXTC 901, in which the peptide sequence is protected and only activated by thrombin at a wound site. More... 

This targeted approach to creating clotting materials at wound sites is the key to the success of Haemostatix’s products. Each of the three products within the current pipeline is designed to treat or prevent different forms of bleeding .

|	Created by One Vision Ltd